Outcome of Board Meeting_Appointment of Statutory Auditors
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board meeting on May 7, 2026 approved multiple key decisions. The company approved audited financial results for Q4 and FY ended March 2026, and recommended a final dividend of Rs. 0.50 per share (10% on Rs. 5 face value), payable by August 31, 2026. The Board appointed S. R. Batliboi & Associates LLP as the new statutory auditors for 5 years, replacing B S R & Co. LLP upon completion of their term at the upcoming AGM. Six new directors are being appointed including former Viatris/Mylan executive Rajiv Malik, biotech veteran Daniel Bradbury, and global health expert Peter Baron Piot. Additionally, the Board approved acquiring the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) through issuance of 87.92 lakh equity shares worth Rs. 330.73 crore to 127 BBL shareholders, and approved a Long-Term Incentive Plan.
The BBL acquisition will make Biocon Biologics a nearly 100% owned subsidiary, simplifying corporate structure. The appointment of pharma veterans to the board could bring strategic expertise. The preferential share issuance will cause minor dilution. Overall, these are positive governance changes aligning with the company's integration strategy.